OBJECTIVES: Methylenetetrahydrofolate reductase (MTHFR) gene is associated with DNA hypomethylation, an established hallmark of human cancer cells. The aim of this study was to examine the effect of MTHFR polymorphism C677T on cervical carcinogenesis in the context of other environmental factors, such as smoking, parity, and age at the first intercourse. METHODS: The study subjects were patients who were pathologically diagnosed with cervical neoplasia and who had a positive result for human papillomavirus (N = 462), and they were compared to normal healthy women as normal controls (N = 454). Genotypes of the patients and control samples were assayed by single base primer extension assay using SNapShot assay kit. RESULTS: Compared with MTHFR C/C, the odds ratio (95% confidence interval) for MTHFR T/T was 1.4 (0.9-2.3) for invasive cervical cancer and 1.3 (0.8-2.3) for cervical intraepithelial neoplasia (CIN) II or III. The risks for invasive cervical cancer were higher with less than 40 years old at diagnosis (2.1, 1.0-4.3), than with over 40 years old at diagnosis (1.2, 0.7-2.2). Current smoking women with early onset with MTHFR T/T had a 4.7 (0.6-36.2) times higher risk of cervical cancer. The risks of MTHFR T/T or C/T also increased for women with an early age of first intercourse or for women with two or more children, as compared with MTHFR C/C. CONCLUSION: Polymorphisms of MTHFR are associated with a higher risk of developing cervical cancer, and in particular for an early onset of cervical carcinogenesis.
OBJECTIVES:Methylenetetrahydrofolate reductase (MTHFR) gene is associated with DNA hypomethylation, an established hallmark of humancancer cells. The aim of this study was to examine the effect of MTHFR polymorphism C677T on cervical carcinogenesis in the context of other environmental factors, such as smoking, parity, and age at the first intercourse. METHODS: The study subjects were patients who were pathologically diagnosed with cervical neoplasia and who had a positive result for human papillomavirus (N = 462), and they were compared to normal healthy women as normal controls (N = 454). Genotypes of the patients and control samples were assayed by single base primer extension assay using SNapShot assay kit. RESULTS: Compared with MTHFR C/C, the odds ratio (95% confidence interval) for MTHFR T/T was 1.4 (0.9-2.3) for invasive cervical cancer and 1.3 (0.8-2.3) for cervical intraepithelial neoplasia (CIN) II or III. The risks for invasive cervical cancer were higher with less than 40 years old at diagnosis (2.1, 1.0-4.3), than with over 40 years old at diagnosis (1.2, 0.7-2.2). Current smoking women with early onset with MTHFR T/T had a 4.7 (0.6-36.2) times higher risk of cervical cancer. The risks of MTHFR T/T or C/T also increased for women with an early age of first intercourse or for women with two or more children, as compared with MTHFR C/C. CONCLUSION: Polymorphisms of MTHFR are associated with a higher risk of developing cervical cancer, and in particular for an early onset of cervical carcinogenesis.
Authors: Ya Li Luo; Ping Ye; Qiong Hua Zhang; Ting Ting Hu; Min Hong Luo; Mei Qing Li; Qing Chen Journal: PLoS One Date: 2012-09-28 Impact factor: 3.240
Authors: Suguna Badiga; Gary L Johanning; Maurizio Macaluso; Andres Azuero; Michelle M Chambers; Nuzhat R Siddiqui; Chandrika J Piyathilake Journal: PLoS One Date: 2014-10-10 Impact factor: 3.240
Authors: Kyu Ri Hwang; Young Min Choi; Jin Ju Kim; Sung Ki Lee; Kwang Moon Yang; Eun Chan Paik; Hyeon Jeong Jeong; Jong Kwan Jun; Sang Ho Yoon; Min A Hong Journal: J Korean Med Sci Date: 2017-12 Impact factor: 2.153